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Abstract
Background: Diabetes mellitus causes the deterioration of smooth muscle cells and interstitial matrix proteins,
including collagen. Collagen and smooth muscle cells are abundant in the lungs, but the effect of diabetes on
airway function and viscoelastic respiratory tissue mechanics has not been characterized. This study investigated the
impact of diabetes on respiratory function, bronchial responsiveness, and gas exchange parameters.
Methods: Rats were allocated randomly to three groups: a model of type 1 diabetes that received a high dose of
streptozotocin (DM1, n = 13); a model of type 2 diabetes that received a low dose of streptozotocin with a high-fat
diet (DM2, n = 14); and a control group with no treatment (C, n = 14). Forced oscillations were applied to assess
airway resistance (Raw), respiratory tissue damping (G), and elastance (H). The arterial partial pressure of oxygen to
the inspired oxygen fraction (PaO2/FiO2) and intrapulmonary shunt fraction (Qs/Qt) were determined from blood
gas samples at positive end-expiratory pressures (PEEPs) of 0, 3, and 6 cmH2O. Lung responsiveness to
methacholine was also assessed. Collagen fibers in lung tissue were quantified by histology.
Results: The rats in groups DM1 and DM2 exhibited elevated Raw, G, H, and Qs/Qt, compromised PaO2/FiO2, and
diminished airway responsiveness. The severity of adverse tissue mechanical change correlated with excessive lung
collagen expression. Increased PEEP normalized the respiratory mechanics, but the gas exchange abnormalities
remained.
Conclusions: These findings indicate that diabetes reduces airway and lung tissue viscoelasticity, resulting in
alveolar collapsibility that can be compensated by increasing PEEP. Diabetes also induces persistent alveolo-capillary
dysfunction and abnormal adaptation ability of the airways to exogenous constrictor stimuli.
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Introduction
Uncontrolled diabetes mellitus (DM) can result in long-
term hyperglycemia that activates various molecular path-
ways [1], leading to inflammation [2], endothelial [3, 4],
smooth muscle cell dysfunction [5], and protein destruc-
tion [6]. These mechanisms involve the formation of
advanced glycation end products (AGEs) [7], which cause
deterioration to the structure and function of matrix pro-
teins and affect matrix–matrix and matrix–cell interac-
tions [8].
The pathophysiological consequences of DM may also
damage the pulmonary endothelium and bronchial
smooth muscle cells, so the lungs can be among the or-
gans most affected by DM [9–12]. Endothelial dysfunc-
tion contributes to the remodeling of the airways and
lung parenchyma related to oxidative stress and the
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overproduction of reactive oxygen species [13–15].
These processes manifest as the sustained contraction of
bronchial smooth muscle cells [13, 14, 16, 17], thickening
of the alveolar walls [10, 18], and changes to the elastin–
collagen matrix in the lung parenchyma [10, 19, 20].
Hyperglycemia also affects type II pneumocyte cells,
resulting in decreased surfactant biosynthesis and secre-
tion [21, 22].
Conflicting results have been reported for the effects
of DM on lung function. Some studies have demon-
strated declines in spirometry outcomes [23–26],
whereas others found no detectable change [27–30].
Possible explanations for this discrepancy include the
dependence of spirometry results on the effort and co-
operation of patients [31, 32], and substantial differences
between study populations, such as the type and severity
of DM, age, and comorbidities. Furthermore, forced ex-
piratory parameters have limited sensitivity to detecting
detrimental changes in lung tissue and peripheral airway
mechanics [9, 27, 30], the aspects of the lung affected
primarily by DM [30, 33]. Thus, it remains unclear how
DM affects airway function and the viscoelastic mechan-
ics of respiratory tissue, including its dissipative and
elastic properties. In particular, it is unknown whether
DM influences the changes in mechanical parameters
that occur with changes in lung volume.
This study aimed to characterize changes in the airway
and respiratory tissue viscoelastic parameters to clarify
the pulmonary consequences of hyperglycemia. There-
fore, we applied a measurement technique that allowed
the exact characterization of these changes in well-
established animal models of type 1 and type 2 DM. We
hypothesized that DM would result in the development
of compromised airway function and changes in airway
responsiveness resulting from the sustained contractile
response of the bronchial smooth muscle, as well as de-
terioration to both the dissipative and elastic compo-
nents of respiratory tissue viscoelasticity. We also
assessed the contribution to the DM-induced changes in
lung function of the loss of lung volume, gas exchange
abnormalities, proliferation, and fiber–fiber interaction
by evaluating changes in the functional residual capacity
(FRC), the arterial partial pressure of oxygen to the in-
spired oxygen fraction (PaO2/FiO2), intrapulmonary
shunt (Qs/Qt), and lung histology.
Materials and methods
Ethical considerations
This study was approved by the National Food Chain
Safety and Animal Health Directorate of Csongrád
County, Hungary (no. XXXII./2098/2018), on September
24, 2018. The procedures were implemented in compli-
ance with the guidelines of the Scientific Committee of
Animal Experimentation of the Hungarian Academy of
Sciences (updated Law and Regulations on Animal Pro-
tection: 40/2013. [II. 14.], the Government of Hungary),
and European Union Directive 2010/63/EU on the pro-
tection of animals used for scientific purposes. The re-
sults were reported in line with the ARRIVE guidelines.
Inducing diabetes
The study used 5-week-old male Wistar rats (mean
weight ± 95% confidence interval, 187.3 ± 3.7 g, n = 42).
During the initial phase of the study protocol, the ani-
mals were housed for 15 weeks under close daily obser-
vation in accordance with the animal welfare assessment
and 3R guidelines. Well-validated models were adapted
to induce models of type 1 and type 2 DM, with proven
hyperglycemia, insulin resistance, and the diffuse degen-
eration of pancreatic cells [34–39]. The 5-week-old rats
were assigned randomly to three protocol groups: model
of type 1 DM (DM1 group, n = 14), model of type 2 DM
(DM2 group, n = 14), and control group (n = 14). They
were fed in accordance with their group allocations
(Fig. 1a): rats in the DM1 and control groups received a
normal diet (fat and protein contents of 3.9 and 20.1%,
respectively), whereas those allocated to the DM2 group
were fed a high-fat diet (Altromin C1080, 47% fat, 18%
protein, 35% carbohydrate; Altromin Spezialfutter
GmbH & Co. KG, Lage, Germany). After a 3-week
period (at the age of 8 weeks), the DM1 group rats were
treated with a single high dose of streptozotocin (STZ,
65 mg/kg) [34, 38], the DM2 group rats were treated
with a low dose (30 mg/kg) of STZ [35–37, 39], and the
controls received the vehicle of the STZ (citrate buffer,
pH 4.4). Before the injection of STZ or vehicle and 1
week after the treatment (age of 9 weeks), fasting glucose
levels were measured from the tail vein using an Accu-
Chek Active blood glucose meter (Roche, Basel,
Switzerland). Four rats in the DM2 group were adminis-
tered a second injection of 30mg/kg STZ treatment be-
cause their fasting glucose level was < 7.8 mmol/l [36, 39].
One animal in the DM1 group was sacrificed after 7 weeks
due to isolation and its unsatisfactory health condition.
Animal preparation
The experiments were performed on week 16 (age of
20 weeks; Fig. 1b). Anesthesia was induced by an in-
traperitoneal injection of sodium pentobarbital (45
mg/kg; Sigma-Aldrich, Budapest, Hungary). After ad-
ministering local anesthesia (subcutaneous lidocaine,
2–4 mg/kg), a polyethylene cannula with an inner
diameter of 18G was inserted into the trachea
through a tracheostomy. The tracheal cannula was
connected to a small animal ventilator (Model 683;
Harvard Apparatus, South Natick, MA, USA), and the
animal was mechanically ventilated (55–60 breaths/
min, tidal volume 7 ml/kg, with a fraction of inspired
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oxygen [FiO2] of 21%). The femoral artery was cathe-
terized for blood pressure measurements and the col-
lection of blood samples. The femoral vein was
cannulated for drug administration and the jugular
vein was secured for drug administration and the col-
lection of venous blood samples. Anesthesia was
maintained with pentobarbital (5 mg/kg, intravenous
(iv.), every 30 min). The rat was placed on a heating
pad (model 507223F; Harvard Apparatus, Holliston,
MA, USA) and its body temperature was maintained
at 37 ± 0.5 °C. The forced oscillation measurements to
evaluate the impedance of the respiratory system were
made under neuromuscular blockade, achieved by the
repeated iv. administration of pipecuronium (0.1 mg/
kg every 30 min; Arduan, Richter-Gedeon, Budapest,
Hungary).
Functional residual capacity
The FRC was measured as described previously [40].
Briefly, the rat was tracheostomized and placed in a
whole-body plethysmography box. The trachea and box
were closed at end-expiration and the measurements
were made while the animal generated breathing efforts
against the closed trachea. The FRC was calculated from
the simultaneously measured tracheal and box pressure
signals by applying the Boyle–Mariotte law [40].
Airway and respiratory tissue mechanics
The input impedance of the respiratory system (Zrs) was
measured by the forced oscillation technique, as de-
scribed previously [41]. Briefly, the tracheal cannula was
connected to a loudspeaker-in-box system, while ventila-
tion was suspended at end-expiration. A small-
amplitude pseudorandom signal (< 1.5 cmH2O, with 23
non-integer multiple-frequency components between 0.5
and 20.75 Hz) was applied to the tracheal cannula
through a wave tube (polyethylene; length 100 cm, in-
ternal diameter 2 mm). To maintain uniform transpul-
monary pressure during the measurements, the pressure
in the loudspeaker box was set to be equivalent to that
of the positive end-expiratory pressure (PEEP) used for
that experiment (0, 3, or 6 cmH2O). During 8-s meas-
urement periods, pressures were measured simultan-
eously at the loudspeaker and tracheal ends of the wave
tube with miniature differential pressure transducers
(Honeywell Differential Pressure Sensor model 24PCE-
FA6D; Honeywell, Charlotte, NC, USA). Zrs was calcu-
lated as the load impedance of the wave tube [41]. At
least four technically acceptable measurements were
made at each stage of the protocol. The mechanical
properties of the respiratory system were characterized
by fitting a well-validated model [42] to the averaged Zrs
spectra. The model comprised frequency-independent
airway resistance (Raw) and airway inertance in series
Fig. 1 Schemes summarizing the pretreatment strategies (a) and the experimental protocol (b). Forced oscillation measurements and
blood gas analyzes were performed at three different positive end-expiratory pressures (0, 3, and 6 cmH2O: PEEP0, PEEP3, and PEEP6,
respectively). Forced oscillation respiratory mechanics were assessed at a PEEP of 3 cmH2O during provocation tests with increasing doses
(2–32 μg/kg/min) of methacholine (MCh) following the baseline measurement (BL). Abbreviations: DM1, model of type 1 diabetes; DM2,
model of type 2 diabetes; C, control group; STZ, streptozotocin in mg/kg; FRC, measurement of functional residual capacity; PREP,
animal preparations
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with a viscoelastic constant-phase tissue unit [42], and
incorporated tissue damping (G) and elastance (H). Tis-
sue histeresivity (η), which characterizes the coupling
between the dissipative and elastic forces within the re-
spiratory tissues was calculated as G/H [43].
Measurement of intrapulmonary shunt fraction and
oxygenation
For the blood gas analyses, 0.1-ml samples of arterial
and central venous blood were collected simultaneously.
The capillary (CcO2), arterial (CaO2), and venous
(CvO2) oxygen contents were evaluated from the blood
gases and used to calculate the intrapulmonary shunt






To characterize the oxygenation efficiency of the lungs
PaO2/FiO2 was calculated from the arterial blood gas
assessments.
Lung tissue histology
After completing the experimental protocol, a midline
thoracotomy was performed and the lungs were fixed by
introducing 4% formaldehyde via the tracheal cannula
with a hydrostatic pressure of 20 cmH2O. The heart-
lung blocks were then removed in one piece from the
thoracic cavity. To visualize the collagen in the lung, tis-
sue samples were fixed in 4% buffered formalin, embed-
ded in paraffin, and 5-μm tissue sections were stained
with Picro Sirius Red staining (Sigma-Aldrich). These
were scanned with a Zeiss Mirax MIDI slide scanner at
a magnification of × 20. At least three representative
0.15-mm2 sized rectangular regions of interest that con-
tained alveoli without bronchi or large vessels were ana-
lyzed in each section. The collagen was segmented and
quantified in the lung tissue sections by using the Train-
able Weka Segmentation plugin in Fiji software [45].
The histological analyses were made by one person who
was blinded for the group allocation.
Experimental protocol
The experimental protocol is summarized in Fig. 1b.
Following a 12-week housing period after the induction
of DM (at the age of 20 weeks), each rat was anesthe-
tized and the trachea was secured. The FRC was mea-
sured, followed by the surgical insertion of the arterial
and venous catheters. Animals were initially ventilated
with a PEEP of 3 cmH2O. A hyperinflation maneuver
was then performed to standardize the volume history.
After 3 min, arterial and venous blood gas samples were
taken simultaneously and the first set of Zrs data was
collected. Blood gas analyses and Zrs recordings were
made at PEEP levels of 0 and 6 cmH2O, in random
order. A period of 3 min was allowed for the animal after
each PEEP step to maintain a steady state condition dur-
ing the data collection. After completing the study on
characterizing the PEEP-dependence, the PEEP was fixed
at 3 cmH2O and a set of Zrs data was collected to estab-
lish the baseline for the bronchoprovocation tests with
doubling doses (2, 4, 8, 16, and 32 μg/kg/min) of i.v.
methacholine (MCh). At each MCh dose, steady-state
bronchoconstriction was established (defined as < 5%
difference in Raw between consecutive measurements)
and forced oscillation Zrs data were measured. After
completing the measurement protocol, each animal was
euthanized by an overdose of pentobarbital and the
lungs were removed for histological analysis.
Statistical analyses
Data are expressed as mean ± standard deviation (SD)
for normally distributed variables, and median with
interquartile range (1st - 3rd quartile) otherwise. The
Kolmogorov–Smirnov test was used to test data distri-
butions for normality; where necessary, a logarithmic
transformation was performed to normalize the data.
Two-way repeated-measures analysis of variance
(ANOVA) with Holm–Sidak post hoc analyses was used
to assess the effects of the PEEP and group allocation on
the respiratory mechanical and oxygenation parameters.
Between group differences in airway responsiveness to
MCh were evaluated with further two-way repeated-
measures ANOVA with Holm–Sidak post hoc analyses.
The MCh doses that elicited a 50% increase in Raw rela-
tive to baseline (PD50) were determined by fitting linear
models to the individual dose–response curves. One-way
ANOVA with Dunn’s post hoc analyses was used to
evaluate the differences between groups in body weights,
blood glucose levels, specific airway and respiratory tis-
sue parameters, PD50, and the results of the histological
analyzes. Correlation between the collagen expression in
the lung tissue and viscoelastic properties of the respira-
tory system was determined by the Pearson correlation
analysis. A sample size estimation for the repeated-
measures ANOVA for the variable Raw, with a power of
0.8 and alpha of 0.05, indicated that at least 10 animals
were required in each group to detect a statistically sig-
nificant difference [46]. The statistical tests were per-
formed with a significance level of p < 0.05.
Results
Body weights, serum glucose levels, and the initial lung
function parameters are summarized in Table 1. At the
end of the 12-week treatment period, the mean body
weight of the rats in the DM1 group was significantly
lower than those in the DM2 and control groups.
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Significant elevations in blood glucose level were ob-
served in the rats of the DM1 and DM2 groups com-
pared to the control animals. The FRC measurements
showed a significant reduction in static lung volume in
the DM1 group rats; however, when the FRC values
were normalized to body weight, they were significantly
higher for the DM1 group rats than for those in the
other two groups. Specific airway and respiratory tissue
parameters were significantly higher in the DM1 and
DM2 groups than in the control group.
Figure 2 shows how the airway and viscoelastic param-
eters of the respiratory tissues varied with the PEEP for
the three groups. Raw was significantly greater in both
groups of diabetic animals than in the control group at
all PEEP levels (p < 0.001). Two-way ANOVAs showed
significant interactions between group and PEEP level
for the parameters G (p < 0.001) and H (p < 0.001), indi-
cating that the treatment affected these parameters’ de-
pendence on PEEP. The dissipative properties of the
respiratory tissues reflected by G were significantly com-
promised in the DM1 group when PEEP = 0 cmH2O.
The respiratory tissue stiffness was elevated in both the
DM1 (p < 0.001) and the DM2 (p = 0.039) groups at all
PEEP levels, with more pronounced differences at low
lung volumes. The dissociated PEEP dependences of G
and H resulted in changes in η that varied between the
groups, with significant decreases observed in the DM1
group for all three levels of PEEP (p < 0.001) and in the
DM2 group when the PEEP was 3 or 6 cmH2O (p =
0.014) compared to the control group.
Airway resistance (left) and its changes relative to the
baseline (right) during the MCh provocation tests are
shown in Fig. 3. Significant elevations in the basal Raw
values were observed in the DM1 (p < 0.001) and DM2
(p < 0.05) groups. These differences remained at the
lower doses of MCh, whereas the absolute value of Raw
became significantly lower in the DM1 rats at the high-
est dose of MCh (p < 0.05). Due to the significantly
higher baseline Raw values in the diabetic rats, the dif-
ferences in the dose-response curves to MCh between
the protocol groups is more obvious when the responses
are expressed as relative changes to baseline (right). In
the control and DM2 groups, elevations in Raw were
statistically significant from the 8 μg/kg/min MCh dose
(p < 0.05), whereas in the DM1 group this increase was
only observed after 16 μg/kg/min (p < 0.05). At the high-
est MCh dose, the MCh-induced relative increases in
Raw were significantly lower in both DM1 and DM2
groups compared to control (p = 0.001). The characteris-
tic shifts in the dose–response curves showed that the
PD50 for MCh was significantly higher for the DM1
group (25.3 ± 20 μg/kg/min) than for the control group
(8.9 ± 3.3 μg/kg/min, p = 0.001) and the DM2 group
(12.7 ± 7.4 μg/kg/min, p = 0.026).
The parameters reflecting the gas exchange properties
of the lungs are summarized in Fig. 4. The rats with
healthy lungs in the control group exhibited moderate
values of intrapulmonary shunt (< 9.3%) and physio-
logical PaO2/FiO2 (> 438mmHg); these indices exhibited
systematic improvements with increasing PEEP to 3 (p <
0.02) and 6 cmH2O (p < 0.05). In the DM2 group, there
was a near-significant tendency for Qs/Qt to be reduced
compared to the control group at a PEEP of 6 cmH2O
(p = 0.065), whereas PaO2/FiO2 was reduced at a PEEP
of 3 cmH2O (p = 0.05) and tended to diminish at a PEEP
of 6 cmH2O (p = 0.069). In the DM1 group at all three
PEEP levels, there were significant increases in the intra-
pulmonary shunt (p < 0.001) associated with markedly
compromised PaO2/FiO2 (p < 0.001). In addition,
changes in the PEEP dependence of the gas exchange
parameters were observed in the DM1 group, with no
monotonous improvements in Qs/Qt and PaO2/FiO2
with increasing PEEP.
Figure 5 shows the expression of collagen in the three
groups. The percentage area of collagen was significantly
higher in both DM groups than in the control group








Body weight (g) 563 ± 49 348 ± 91* 529 ± 76# < 0.001
Blood glucose (mmol/l) 5.8 (5.6–6.1) 29.9* (25.8–35.0) 14.75* (7.0–27.3) < 0.001
FRC (ml) 4.3 ± 0.5 3.6 ± 0.6* 4.4 ± 0.8# 0.003
FRCN (ml/kg) 7.5 (6.8–8.7) 10.2
* (8.6–1.3) 8.1# (6.7–9.3) 0.003
SRaw (cmH2O.s) 0.23 (0.19–0.24) 0.27
* (0.24–0.32) 0.27* (0.23–0.34) 0.004
SG (cmH2O) 3.1 (2.7–3–3) 3.4
* (3.2–4.0) 3.6* (3.0–4.4) 0.023
SH (cmH2O) 12.0 ± 2.7 17.3 ± 4.9
* 17.2 ± 5.8* 0.007
Main outcome parameters in the control rats (Group C) and in model of type 1 (Group DM1) and type 2 (Group DM2) diabetes mellitus presented as mean ± SD
(Body weight, FRC and SH as normally distributed variables) and interquartile range (Q1 - Q3; Blood glucose, FRCN, SRaw, SG). FRC: functional residual capacity,
FRCN: functional residual capacity normalized to body weight (FRC/BW), SRaw: specific airway resistance (Raw × FRC), SG: specific respiratory tissue damping (G ×
FRC), SH: specific airway resistance (H × FRC); all obtained without applying positive end-expiratory pressure. p: results of the one-way ANOVA tests and ANOVA on
ranks. *: p < 0.05 vs. Group C, #: p < 0.05 between Groups DM2 and DM1 by using Dunn’s post-hoc analyses
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(p < 0.001). The collagen content of the lung paren-
chyma was greater in the DM1 group than in the DM2
group (p < 0.001).
Figure 6 shows the relationship between the percent-
age area of collagen obtained by lung histology and the
viscoelastic dissipative and elastic mechanical parame-
ters. There were significant correlations between the
histology and both tissue mechanical indices, G and H,
with correlation coefficients of 0.67 (p < 0.001) and 0.63
(p < 0.001), respectively.
Discussion
The characterization of the pulmonary effects of DM in
this study revealed detrimental changes in airway func-
tion, viscoelastic tissue mechanics, gas exchange, and
collagen expression in the lung, with more severe mani-
festations in the rat model of type 1 DM than in that for
type 2 DM. The increase in the basal airway tone with
DM was associated with compromised dissipative and
elastic tissue mechanics. The model of type 1 DM also
showed diminished airway responsiveness to an exogen-
ous cholinergic stimulus. These adverse mechanical and
functional changes were accompanied by an increased
intrapulmonary shunt and impaired PaO2/FiO2. Increas-
ing the lung volume had a beneficial effect on the lung
mechanics in both diabetic groups, whereas it had no
benefit on gas exchange.
This study used well-established models to induce type
1 and 2 DM [34–39]. Type 1 DM was induced by a sin-
gle high dose of STZ to cause the destruction of the
Fig. 2 Airway and viscoelastic respiratory tissue mechanical parameters. Measurements obtained at positive end-expiratory pressures of 0, 3, and
6 cmH2O (PEEP0, PEEP3, and PEEP6, respectively) in control rats (closed circles, C, n = 14) and in rats in the type 1 diabetes (DM1, open squares,
n = 13) and type 2 diabetes (DM2, open triangles, n = 14) groups. The symbols and error bars represent the mean and SD values, respectively. *
p < 0.05 vs. PEEP0 within a group; † p < 0.05 vs. PEEP3; # p < 0.05 vs. C within a PEEP. Abbreviations: Raw, airway resistance; G, tissue damping
(resistance); H, tissue elastance; η, tissue histeresivity (= G/H)
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pancreas, whereas type 2 DM was induced by a low dose
of STZ to cause diffuse degeneration of the pancreatic
cells, combined with a high-fat diet. As a result of these
treatments, the blood glucose levels in both DM groups
were markedly higher after 12 weeks than those of the
control group. The body weight of the type 1 DM group
rats was reduced, which can be explained by insulin defi-
ciency [47, 48]. As with other chronic complications of
DM, the pulmonary complications would be expected to
manifest in the late stage of the condition [12]. For this
reason, a 12-week period was allowed for the animals to
develop lung dysfunction. This long period with
Fig. 3 Airway resistance (Raw, left) and its changes relative to the baseline (BL) values (right) during the methacholine provocation tests in
control rats (closed circles, C, n = 14), in rats in the type 1 diabetes (DM1, open squares, n = 13) and type 2 diabetes (DM2, open triangles, n = 14)
groups. The symbols and error bars represent the mean and SD values, respectively. * p < 0.05 vs. BL within a group; # p < 0.05 vs. C within a
condition; † p < 0.05 vs. DM2 within a condition
Fig. 4 The intrapulmonary shunt fraction (Qs/Qt) and (PaO2/FiO2). Measurements obtained at positive end-expiratory pressures of 0, 3, and 6
cmH2O (PEEP0, PEEP3, and PEEP6, respectively) in control rats (closed circles, C, n = 14) and in rats in the type 1 diabetes (DM1, open squares, n =
13) and type 2 diabetes (DM2, open triangles, n = 14) groups. The symbols and error bars represent the mean and SD values, respectively. * p <
0.05 vs. PEEP0 within a group; # p < 0.05 vs. C within a PEEP; † p < 0.05 vs. DM2 within a PEEP
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Fig. 5 Collagen expression in the lung. Areas of collagen obtained from lung histology (left) and representative lung tissue sections in control
rats (C, n = 14) and in rats in the type 1 diabetes (DM1, n = 13) and type 2 diabetes (DM2, n = 14) groups. * p < 0.05 vs. C; # p < 0.05 vs. DM1
Fig. 6 Correlation between the collagen and the viscoelastic parameters of the lung. Correlations between the percentage areas of collagen
obtained by lung histology and forced oscillation mechanical parameters for tissue damping (G) and elastance (H) in control rats (C, n = 14) and
in rats in the type 1 diabetes (DM1, n = 13) and type 2 diabetes (DM2, n = 14) groups. The solid line indicates the linear regression curve
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markedly elevated serum glucose levels allowed the de-
velopment of adverse pulmonary symptoms without a
fatal outcome.
Forced oscillatory assessment of airway mechanics
showed that DM caused a deterioration of basal Raw,
with more severe changes occurring in the type 1 DM
model rats (Fig. 2 PEEP0). As these changes were also
apparent in the specific airway resistance values (Table 1)
of both DM groups, the differences in lung size cannot
solely be accounted for by the compromised airway me-
chanics. Instead, these pathological changes in the air-
ways may be explained by the decreased vagal tone [49],
excessive mucus production [50], low-grade chronic in-
flammation [51], activation of inflammatory pathways
[52], or bronchial smooth muscle cell proliferation [5,
53]. The present study’s finding of increased airway tone
in the DM rat models is in qualitative agreement with
the results of previous studies that assessed airway re-
sistance in DM [27, 54], providing supporting evidence
for the potential development of chronic airway obstruc-
tion in patients with DM.
The effects of DM on the mechanical properties of the
lung tissue has been studied in an ex-vivo experiment, and
the results were limited to assess the elastic behavior of
the lung parenchyma [55] However, dissipative properties
of the lung tissue play an important role in determining
the physiological lung mechanics and the changes of this
component is characteristic in various lung diseases [56].
In the present study using an in-vivo setting, significant
deteriorations were observed in the viscoelastic mechan-
ical parameters of the respiratory tissues in both groups of
diabetic rats (Fig. 2), and this adverse change affected both
the dissipative and elastic properties. These differences
compared to the control group remained after
normalization of the values to the FRC (Table 1), indicat-
ing that intrinsic changes to the dissipative and elastic
properties of the respiratory tissues can be anticipated.
Collagen is the main determinant of overall lung tissue
viscoelasticity [57, 58]. In the present study, the volume of
collagen increased in the DM models, in agreement with
results reported for patients with DM [59] (Fig. 5). There
were significant correlations between the histological and
mechanical findings (Fig. 6), which suggested that the
overexpression of collagen may be a primary cause of the
compromised tissue damping and elastance observed in
DM. The underlying pathophysiological mechanisms re-
sponsible for this extracellular matrix remodeling may be
related to the activation of pathological pathways that
contribute to the formation of AGEs, which also stimulate
the production of extracellular matrix components, in-
cluding collagens, thereby affecting the interactions of the
extracellular matrix [1].
Increasing numbers of patients with DM require surgi-
cal procedures that involve mechanical ventilation,
which has increased the burden on healthcare providers
[60, 61]. There is, therefore, a need for awareness that
adequate mechanical ventilation should be provided for
these patients. Open lung strategies require the applica-
tion of an appropriate PEEP; however, the impact of dif-
ferent levels of PEEP on respiratory function in DM has
not been clarified. Our findings demonstrated that the
between-group differences in the airway resistance and
in the tissue mechanical parameters representing visco-
elastic dissipation and elastance disappeared at a moder-
ately elevated PEEP (6 cmH2O; Fig. 2). The excessive
PEEP dependence of the respiratory mechanical parame-
ters was consistent with the diminished surfactant func-
tion reported previously in models of DM [21, 22]. It
suggests that applying PEEP can have a beneficial effect
on respiratory mechanics in this metabolic disease. The
mechanical improvements were reflected in the de-
creased intrapulmonary shunt and increased PaO2/FiO2
in the DM rats when a PEEP of 3 cmH2O (Fig. 4) was
applied. Nevertheless, substantial differences remained
even with elevated PEEP in both groups of DM rats; this
can be attributed to the persistent alveolar-capillary bar-
rier damage observed in DM [26, 59, 62]. The type-II
pneumocyte and surfactant layer damage [21, 22] along
with the low-grade inflammation [26] observed in DM
can contribute to the alveolo-capillary dysfunction. No-
ticeably, there was recurrent deterioration of PaO2/FiO2
and Qs/Qt in the type 1 DM rats at a PEEP of 6 cmH2O.
This group would be expected to develop the well-
established adverse pulmonary vascular consequences of
hyperglycemia [63]. Accordingly, formation of AGEs as
detailed above contributes to a proliferation of pulmon-
ary endothelial and vascular smooth muscle cells and
thicker basal lamina [64], which may have resulted in
the intra-acinar and alveolar arterioles becoming prone
to collapse when the PEEP exerted an external mechan-
ical load on the capillary network.
An important physiological feature of airways is the
adaptation of their caliber in response to exogenous stim-
uli. The results for the type 1 DM group demonstrated di-
minished airway responsiveness to MCh, which indicated
that the adaptation ability of the bronchomotor tone had
been severely compromised. Pathophysiological mecha-
nisms that may have been involved in the decreased airway
responsiveness include compromised vagal tone develop-
ment due to autonomic diabetic neuropathy [49, 65],
smooth muscle cell dysfunction [66], and/or epithelial
damage [13]. Hyperinsulinemia, insulin resistance and
hyperglycemia can lead to hyperproliferation and pheno-
type changing of the airway and bronchial smooth muscle
cells and induce tracheal wall thickening [5, 53]. The
smooth muscle cell damage might occur due to various
factors, for instance disturbances in the nitric oxide syn-
thesis [13], TGF-β and Rho-associated protein kinase
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pathway activation [16, 67, 68]. Nonetheless, conflicting re-
sults have been reported for the effects of DM on airway
responsiveness. The findings of the present study are con-
sistent with earlier findings of a reduction in the bronchial
response to cholinergic stimuli in DM [13, 29, 69]. Previ-
ous reports of no change in airway responsiveness
[28, 66, 70] or the development of airway hyperre-
sponsiveness [16, 17, 71] may be explained by the in-
sensitivity of the methods to assess airway function
[66], the lack of airway innervation [16, 17, 70], or
the involvement of confounding factors, such as,
smoking, genetic differences and/or phenotype, and
the duration of DM [28, 71]. Furthermore, in previ-
ous clinical studies, diabetes was often associated
with comorbidities affecting the respiratory system,
which may cause variation in the manifested pulmon-
ary effects, and can contribute to the discordant re-
sults in the literature.
Several methodological aspects of the present study
warrant consideration. As well-established models were
adapted in the present study to produce the most im-
portant features of DM, including hyperglycemia and in-
sulin deficiency, verification of the effectiveness of the
STZ treatments was limited to evaluating serum glucose
levels; a detailed characterization of the resulting meta-
bolic profile would go beyond the focus of the present
investigation. The models of type 1 and type 2 DM dif-
fered only in the dose of STZ and the diet regimen. The
high dose of STZ administered to the rats in the type 1
DM group was likely to destroy most of the pancreatic
β-cells, whereas less severe β-cell destruction in the type
2 DM group was complemented by a high-fat diet to in-
duce a combination of impaired insulin production and
peripheral insulin resistance [35, 48]. The difference in
body weight between the groups suggested marked dif-
ferences in their metabolic status; however, the respira-
tory consequences were analogous in the two DM
groups, with symptoms differing only in severity. This
study was designed to focus primarily on the changes in
the mechanical properties of the respiratory system in
diabetes. However, there are plethora of diagnostic tools
to characterize pulmonary dysfunction both at on organ
and at cellular levels. Analyses of bronchoalveolar lavage
fluid to assess altered surfactant function, or quantitative
collagen and smooth muscle cell assays by using immu-
nohistochemistry methods would give further insights
into the underlying mechanisms; these methods may be
subjects of forthcoming investigations.
Conclusion
In summary, distinct measurements of airway and re-
spiratory tissue viscoelastic parameters in models of type
1 and type 2 DM showed evidence of detrimental
changes in both compartments. The decline in airway
function was reflected in elevated airway resistance and
abnormal adaptation of the airways to exogenous con-
strictor stimuli. Lung tissue remodeling was manifested
in compromised viscoelastic tissue mechanics, which af-
fected dissipative and elastic properties, and the concur-
rent overexpression of collagen fibers in the extracellular
matrix. These detrimental mechanical defects were over-
come by applying PEEP, which demonstrated alveolar
collapsibility in DM. However, even with the application
of PEEP, gas exchange parameters remained compro-
mised in the models of type 1 and type 2 DM, even dete-
riorated further in the type 1 DM model, indicating
alveolo-capillary dysfunction. These findings may con-
tribute to an improved understanding of the pulmonary
consequences of DM and hold promise for the advance-
ment of therapeutic interventions. PEEP titration during
mechanical ventilation guided by respiratory mechanical
parameters might be beneficial for this increasingly
prevalent patient population.
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